Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.
A new study shows that patients who initiated treatment with blood pressure or cholesterol medications were more likely to reduce activity and gain weight.
AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.
Invasive methods did not perform better than drug treatment in patients with stable ischemic heart disease
Officials with the FDA have approved a new indication and label expansion for icosapent ethyl (Vascepa, Amarin).
Reduces risk for heart failure and cardiovascular disease hospitalizations.